Sugi Predict

Sugi Predict / Compounds / SCHEMBL5660685

SCHEMBL5660685

SCHEMBL5660685

CC(=O)c1ccccc1-c1nc(C(=O)N[C@H]2C[C@H]3CC[C@]2(C)C3(C)C)cs1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ CNR2 P34972 8/20 0.45
▸ CNR1 P21554 6/20 0.45
▸ EPHX2 P34913 7/20 0.45
▸ TNKS O95271 1/20 0.38
▸ HTR3E A5X5Y0 1/20 0.37
▸ HTR3B O95264 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ HTR3D Q70Z44 1/20 0.37
▸ HTR3C Q8WXA8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13548758 1.00 MEN1 (0.48) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL5661906 0.86 NPSR1 (0.53) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL5661061 0.86 NPSR1 (0.53) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL14463789 0.78 CHRM1 (0.41) NPSR1TNKSHTR3EHTR3BCHRNA7
SCHEMBL2027225 0.76 TYR (0.61) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL3543022 0.76 TYR (0.61) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL5662881 0.75 TDP1 (0.54) EPHX2TNKSHTR3EHTR3BCHRNA7
SCHEMBL29494626 0.75 MEN1 (0.60) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL3535569 0.74 THRB (0.51) KMT2ACNR2CNR1EPHX2HTR3E
SCHEMBL14464273 0.73 HTR3E (0.36) TNKSHTR3EHTR3BCHRNA7HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 — — US disclosed
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 — — US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 — — US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 — — US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 MEN1 702/4885HTT 3697/4885KMT2A 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.